#ORPH Open Orphan – £1.5m Contract renewal for Venn Life Sciences
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that Venn Life Sciences (“Venn”), a subsidiary of Open Orphan, has signed a contract renewal with a major global pharmaceutical client worth £1.5m over two years. The renewed contract will commence in January 2022, with […]
Open Orphan #ORPH – Major year-on-year revenue growth and profitable H1 2021 performance following a year of turnaround and transition in 2020
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its unaudited interim results for the six months ended 30 June 2021. These results show a continued pattern of profitability from Q4 2020 to a firmly profitable position […]
Open Orphan #ORPH – DNDi Phase II trial to support river blindness drug
Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) which is the world leader in testing vaccines and antivirals using human challenge clinical trials, announces a contract to supply consultancy services to support a Phase II trial in Onchocerciasis Disease, an infectious disease commonly known as river blindness. Venn Life Sciences […]
Open Orphan (ORPH) Final Results to 31 December 2020
Final Results to 31 December 2020 Important year of transition following the various merger and acquisition activities in 2019 and January 2020 Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its audited results for […]
Open Orphan #ORPH – Exercise of Warrants & TVR
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , has received notice of exercise of warrants by investors, who participated in the Venn loan note financing in December 2018, over 404,806 ordinary shares of 0.1 pence […]
Open Orphan #ORPH – New contract win with Oxford BioTherapeutics
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its subsidiary Venn Life Sciences (“Venn”) has been awarded a contract for a study with Oxford BioTherapeutics, a clinical stage oncology company with a pipeline of immune-oncology and antibody-drug […]
Open Orphan #ORPH – Exercise of Investor Warrants by Investors, Issue of Shares and TVR
Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organization (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , has received notice of exercise of warrants by investors who participated in the Venn loan note financing in December 2018 over 1,349,349 ordinary shares of 0.1 pence each in […]
Open Orphan #ORPH – Contract extension with Carna Biosciences
Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a further contract renewal with Carna Biosciences, Inc. (“Carna”), extending its integrated drug development consultancy services with Venn Life Sciences (“Venn”), part of Open Orphan plc. Carna […]
Open Orphan PLC #ORPH – Venn Life Sciences contract wins
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce its subsidiary Venn Life Sciences (“Venn”) has been awarded two new contracts. The first contract, which will commence immediately, is a COVID-19 […]
Open Orphan #ORPH – Contract renewal with top-3 global pharmaceutical client
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a further contract renewal with a major top-3 global pharmaceutical client extending its consultancy services to end of December 2021. This follows on from the announcement made on […]